Phio Pharmaceuticals Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on August 9, 2019, covering events occurring on August 7, 2019. Phio Pharmaceuticals Corp. (PHIO), a Delaware corporation listed on the Nasdaq Capital Market, reported the entry into a material definitive agreement and the departure of a director.
Key Financial Metrics and Capital Structure
The filing does not provide specific revenue, profit, cash flow, or margin data for a reporting period. Instead, it details a new financing facility:
- Facility Size: Up to $10,000,000 in common stock sales via an At-The-Market (ATM) facility with Lincoln Park Capital Fund, LLC (LPC).
- Commitment Fee: Issuance of 500,000 shares of Common Stock to LPC as a commitment fee (no cash proceeds received).
- Issuance Limits: Limited to 5,015,730 shares (19.99% of outstanding shares) unless shareholder approval is obtained or specific price thresholds are met.
- Ownership Cap: LPC cannot beneficially own more than 9.99% of the Common Stock.
- Term: 30-month period commencing upon the effectiveness of the registration statement.
- Use of Proceeds: Working capital and general corporate purposes.
Material Changes and Corporate Governance
Financing Agreement: The Company entered into a Purchase Agreement and Registration Rights Agreement with LPC, granting the Company the right to sell shares at market prices subject to daily volume limits (Regular Purchase Amount of 200,000 shares or $50,000, whichever is greater).
Director Departure: Mr. Keith L. Brownlie notified the Board of his intention not to stand for reelection at the 2019 Annual Meeting due to retirement. His resignation is not related to any disagreement regarding the Company's operations, policies, or financial status. He will serve until the election of directors at the Annual Meeting.
Outlook, Risks, and Contingencies
Management Commentary: Actual sales under the Purchase Agreement depend on market conditions, trading prices, and the Company's funding determinations. The Company retains the right to terminate the agreement at any time without penalty.
Risks and Contingencies:
- Dilution: The issuance of Commitment Shares and potential future sales under the facility will dilute existing shareholders.
- Market Conditions: Proceeds are not guaranteed and depend on the Company's discretion and market prices.
- Restrictions: The Company is restricted from entering into "variable rate" transactions with third parties for a defined period.
Key Facts for Investor Verification
- Verify the exact number of shares issued as the commitment fee (500,000) and the resulting immediate dilution.
- Confirm the status of the registration statement required to activate the $10 million facility.
- Review the specific price thresholds in the Purchase Agreement that limit the Company's ability to sell shares if the stock price falls.
- Monitor the 2019 Annual Meeting to confirm the election of a replacement director for Mr. Brownlie.
- Check subsequent filings for any actual sales of shares under the facility and the resulting cash proceeds.